334
Participants
Start Date
January 12, 2017
Primary Completion Date
September 13, 2019
Study Completion Date
March 26, 2020
roxadustat
Oral administration
DA
Subcutaneous administration
Site JP00009, Kasugai
Site JP00030, Nagoya
Site JP00051, Nagoya
Site JP00021, Toyohashi
Site JP00003, Sakura
Site JP00038, Matsuyama
Site JP00044, Matsuyama
Site JP00008, Kitakyushu
Site JP00013, Kitakyushu
Site JP00040, Kitakyushu
Site JP00057, Kitakyushu
Site JP00042, Kurume
Site JP00041, Tajimi
Site JP00002, Maebashi
Site JP00037, Hatsukaichi
Site JP00050, Kure
Site JP00049, Aasahikawa
Site JP00007, Sapporo
Site JP00064, Sapporo
Site JP00022, Amagasaki
Site JP00066, Nishinomiya
Site JP00052, Hitachi
Site JP00017, Kasama
Site JP00028, Koga
Site JP00053, Naka
Site JP00023, Sashima-gun
Site JP00019, Toride
Site JP00046, Tsuchiura
Site JP00035, Kanazawa
Site JP00031, Morioka
Site JP00047, Fujisawa
Site JP00001, Kamakura
Site JP00016, Yokohama
Site JP00048, Yokohama
Site JP00012, Sendai
Site JP00036, Ueda
Site JP00059, Higashiosaka
Site JP00005, Izumisano
Site JP00011, Sakai
Site JP00069, Yao
Site JP00029, Ageo
Site JP00004, Koshigaya
Site JP00020, Koshigaya
Site JP00025, Adachi-ku
Site JP00043, Bunkyo-ku
Site JP00063, Chiyoda-ku
Site JP00067, Hino
Site JP00015, Koto-ku
Site JP00024, Minato-ku
Site JP00006, Musashino
Site JP00060, Ōta-ku
Site JP00062, Tachikawa
Site JP00014, Fukui
Site JP00033, Fukuoka
Site JP00065, Fukuoka
Site JP00032, Hiroshima
Site JP00039, Hiroshima
Site JP00045, Kyoto
Site JP00018, Nagano
Site JP00068, Nagano
Site JP00026, Niigata
Site JP00055, Okayama
Site JP00056, Osaka
Site JP00061, Osaka
Site JP00034, Ōita
Site JP00010, Toyama
Lead Sponsor
Collaborators (1)
FibroGen
INDUSTRY
Astellas Pharma Inc
INDUSTRY